ArticleNeurochemical research2026
Cryptotanshinone Targets Ferroptosis in Glioma via the EGFR/ROS Signaling Pathway.
Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
To investigate the regulatory effects of cryptotanshinone (CTS) on the biological behavior of glioma cells and its underlying molecular mechanisms, with a particular focus on the role of the epidermal growth factor receptor/reactive oxygen species (EGFR/ROS) pathway in ferroptosis-mediated antitumor activity. Glioma cell behaviors were monitored through Cell Counting Kit-8 (CCK-8), colony formation, wound healing, and Transwell assays. Intracellular and tumor tissue levels of reactive oxygen species (ROS), mitochondrial membrane potential (MMP), ferrous iron (Fe²⁺), glutathione/glutathione disulfide (GSH/GSSG) ratio, and malondialdehyde (MDA) were assessed. Glutathione peroxidase 4 (GPX4), solute carrier family 7 member 11 (SLC7A11), acyl-CoA synthetase long-chain family member 4 (ACSL4), epidermal growth factor receptor (EGFR), and Ki67 expression was examined using western blotting and immunohistochemistry. Network pharmacology and molecular docking were employed to predict potential cryptotanshinone targets. An in vivo glioma model was created by implanting tumor cells into nude mice. CTS inhibited glioma cell malignant phenotype, while promoting ROS accumulation, MMP loss, Fe²⁺ elevation, and GSH depletion. CTS also modulated ferroptosis-associated molecules, characterized by downregulation of GPX4 and SLC7A11 and upregulation of ACSL4. EGFR was identified as a central target, which was experimentally validated to mediate the antitumor and ferroptosis-inducing effects of CTS. In vivo, CTS suppressed tumor growth and activated ferroptosis, whereas EGFR overexpression partially reversed these protective effects. CTS induces ferroptosis in glioma cells by inhibiting EGFR and enhancing ROS signaling, thereby suppressing tumor proliferation and invasion.
Indexed as
Identifiers
42348047What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.